Search | Clinical Trials Finder

Conditions: Melanoma
Interventions: cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 28
States / cities: La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Docetaxel, Gemcitabine, Lurbinectedin (PM01183); Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: INCB013739, Placebo comparator matching INCB013739, Metformin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Artesia, California • Calabasas, California + 54 more

Conditions: Breast Cancer
Interventions: BMS-754807, letrozole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 14 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Lenvatinib, Lenvatinib matched placebo, BSC; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Casa Grande, Arizona • Tucson, Arizona • Gilroy, California + 8 more

Conditions: Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasms, Pancreatic Diseases, Digestive System Diseases, Endocrine System Diseases, Gemcitabine, Antimetabolites, Antineoplastic
Interventions: nab-Paclitaxel, Gemcitabine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 866 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 107
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more

Conditions: Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Interventions: MEDI-573 (1 of 3 doses), Sorafenib; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Oxnard, California • Golden Springs, Colorado • Las Vegas, Nevada

Conditions: Melanoma
Interventions: Dabrafenib, Vemurafenib, Trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 704 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Gilbert, Arizona • Beverly Hills, California + 30 more

Conditions: Diabetic Retinopathy
Interventions: triamcinolone acetonide; Drug
Lead sponsor: Edward Hines Jr. VA Hospital; Federal
Eligibility: 25 Years to 80 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Asthma
Interventions: Symbicort pMDI, budesonide pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 12,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 160
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: BI 765063, Ezabenlimab, BI 836880, Cetuximab, Investigator´s Choice Chemotherapy; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Cancer
Interventions: Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed Disodium Heptahydrate; Drug · Biological
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 1,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 434
States / cities: Anniston, Alabama • Fairbanks, Alaska • Fairfield, California + 312 more

Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Cabazitaxel, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Prednisone; Procedure · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 174
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 129 more

Conditions: Osteoarthritis
Interventions: PH-797804, Placebo, Naproxen, Naproxen + PH-797804; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 26
States / cities: Paramount, California • Spring Valley, California • Valley Village, California + 20 more

Conditions: Melanoma
Interventions: Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 35 more

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Ulcer Foot, Leg Ulcer
Interventions: Standard of Care-DFU, AmnioCore - DFU, Amnio Quad-Core - DFU, Standard of Care-VLU, Amnio Tri-Core - VLU, Amniocore Pro +; Other
Lead sponsor: Stability Biologics; Industry
Eligibility: 21 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Circleville, Ohio

Conditions: Healthy
Interventions: RPV LA, CAB LA; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Neoplasms
Interventions: BI 765179, Ezabenlimab, Pembrolizumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more

Conditions: Transplants and Implants
Interventions: plerixafor, Bortezomib, plasmapheresis; Drug · Other
Lead sponsor: E. Steve Woodle; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Neoplasms, Head and Neck
Interventions: Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Kansas City, Missouri • Charlotte, North Carolina

Conditions: Idiopathic Parkinson's Disease (PD)
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years to 79 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Colorectal Cancer
Interventions: Pembrolizumab, Binimetinib, Oxaliplatin, Leucovorin, 5-Fluorouracil [5-FU], Irinotecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: ON 01910.Na, Gemcitabine; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 30
States / cities: La Jolla, California • Palm Springs, California • Salinas, California + 27 more

Search by objective public record fields.

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

PST/Laser v. Laser Alone for CSME

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

Modified Multi-Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of DFU and VLUs

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Quantitating the Impact of Plerixafor

Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

MER Versus MRI Guidance DBS in Parkinson's Disease

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer